Trial Outcomes & Findings for A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users. (NCT NCT06532357)

NCT ID: NCT06532357

Last Updated: 2025-08-22

Results Overview

Participants responded about satisfaction with treatment for pain intensity using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.

• Recruitment status: COMPLETED
• Target enrollment: 1536 participants
• Primary outcome timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day
• Results posted on: 2025-08-22

Participant Flow

In this study, data was gathered between 30 October 2023 to 20 May 2024 from users of the Migraine Buddy application in the US who answered a survey about their acute treatments (rimegepant, or triptans) for migraine, displayed on the home page of the application. For the purpose of this retrospective study, only questions related to treatment satisfaction were analyzed.

As pre-specified, only variables/data collected were the self-reported satisfaction of Migraine Buddy users via a questionnaire accessible from the home screen of the application. Users completed the satisfaction questions only once for each current acute migraine treatment. A total of 1536 participants were enrolled in this study who completed the survey. There were few participants who were not exclusive and completed survey for both rimegepant and triptans.

Participant milestones

Measure	Rimegepant This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Period 1: Rimegepant User Survey STARTED	708	0
Period 1: Rimegepant User Survey COMPLETED	708	0
Period 1: Rimegepant User Survey NOT COMPLETED	0	0
Period 2: Triptans User Survey STARTED	0	845
Period 2: Triptans User Survey COMPLETED	0	845
Period 2: Triptans User Survey NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study.

Participants responded about satisfaction with treatment for pain intensity using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.

Outcome measures

Measure	Rimegepant n=708 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans n=845 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity Dissatisfied	39 Participants	42 Participants
Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity Satisfied	539 Participants	625 Participants
Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity Neutral	130 Participants	178 Participants

PRIMARY outcome

Timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study.

Participants responded about satisfaction with of attack duration using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.

Outcome measures

Measure	Rimegepant n=708 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans n=845 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Number of Participants Classified as Per Responses for Satisfaction With of Attack Duration Satisfied	524 Participants	571 Participants
Number of Participants Classified as Per Responses for Satisfaction With of Attack Duration Neutral	145 Participants	222 Participants
Number of Participants Classified as Per Responses for Satisfaction With of Attack Duration Dissatisfied	39 Participants	52 Participants

PRIMARY outcome

Timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study.

Participants responded about satisfaction with speed of action using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.

Outcome measures

Measure	Rimegepant n=708 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans n=845 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Number of Participants Classified as Per Responses for Satisfaction With Speed of Action Satisfied	506 Participants	524 Participants
Number of Participants Classified as Per Responses for Satisfaction With Speed of Action Neutral	154 Participants	272 Participants
Number of Participants Classified as Per Responses for Satisfaction With Speed of Action Dissatisfied	48 Participants	49 Participants

PRIMARY outcome

Timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study.

Participants responded about satisfaction with migraine-Induced cognitive impact using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.

Outcome measures

Measure	Rimegepant n=708 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans n=845 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Number of Participants Classified as Per Responses for Satisfaction With Migraine-Induced Cognitive Impact Satisfied	430 Participants	384 Participants
Number of Participants Classified as Per Responses for Satisfaction With Migraine-Induced Cognitive Impact Neutral	237 Participants	377 Participants
Number of Participants Classified as Per Responses for Satisfaction With Migraine-Induced Cognitive Impact Dissatisfied	41 Participants	84 Participants

PRIMARY outcome

Timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study.

Participants responded about satisfaction with relief of other symptoms using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment. Other symptoms included following parameters: photophobia, phonophobia, nausea, vomiting, sensitivity to light/sound/odors).

Outcome measures

Measure	Rimegepant n=708 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans n=845 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Number of Participants Classified as Per Responses for Satisfaction With Relief of Other Symptoms Satisfied	418 Participants	478 Participants
Number of Participants Classified as Per Responses for Satisfaction With Relief of Other Symptoms Neutral	243 Participants	301 Participants
Number of Participants Classified as Per Responses for Satisfaction With Relief of Other Symptoms Dissatisfied	47 Participants	66 Participants

PRIMARY outcome

Timeframe: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.

Participants responded about satisfaction of tolerability using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.

Outcome measures

Measure	Rimegepant n=447 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with rimegepant. No intervention was administered in this study.	Triptans n=845 Participants This arm included participants who used Migraine buddy application and answered the survey about satisfaction with Triptans. No intervention was administered in this study.
Number of Participants Classified as Per Responses for Satisfaction of Tolerability Satisfied	385 Participants	554 Participants
Number of Participants Classified as Per Responses for Satisfaction of Tolerability Neutral	50 Participants	229 Participants
Number of Participants Classified as Per Responses for Satisfaction of Tolerability Dissatisfied	12 Participants	62 Participants

Adverse Events

Rimegepant

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Triptans

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 8007181021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Results disclosure agreements

• Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
• Publication restrictions are in place

Restriction type: OTHER